Cargando…
Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents
BACKGROUND: Heterologous prime-boost SARS-CoV-2 vaccination is a widely accepted strategy during the COVID-19 pandemic, which generated a superior immune response than homologous vaccination strategy. OBJECTIVE: To describe immunogenicity of heterologous prime-boost vaccination with inactivated vacc...
Autores principales: | Puthanakit, Thanyawee, Nantanee, Rapisa, Jaru-Ampornpan, Peera, Chantasrisawad, Napaporn, Sophonphan, Jiratchaya, Meepuksom, Thutsanun, Jupimai, Thidarat, Sodsai, Pimpayao, Anugulruengkitt, Suvaporn, Hirankarn, Nattiya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422341/ https://www.ncbi.nlm.nih.gov/pubmed/36059600 http://dx.doi.org/10.1016/j.jvacx.2022.100211 |
Ejemplares similares
-
Immunogenicity of BNT162b2 in children 6 months to under 5 years of age with previous SARS-CoV-2 infection, in the era of Omicron predominance
por: Nantanee, Rapisa, et al.
Publicado: (2023) -
Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents
por: Puthanakit, Thanyawee, et al.
Publicado: (2022) -
A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222
por: Nantanee, Rapisa, et al.
Publicado: (2022) -
A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines
por: Nanthapisal, Sira, et al.
Publicado: (2022) -
Immunogenicity to SARS-CoV-2 Omicron variant among school-aged children with 2-dose of inactivated SARS-CoV-2 vaccines followed by BNT162b2 booster
por: Chantasrisawad, Napaporn, et al.
Publicado: (2022)